Introduction
“The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems is called as Pharmacovigilance”. [WHO, 2002]
Pharmacovigilance medical writing encompasses all stages of drug development, starting from the initial clinical trials to the essential report submissions required for market authorization and continuing into the post-marketing phase. This comprehensive involvement ensures that drug safety information is meticulously documented, communicated, and updated throughout the lifecycle of the drug. By addressing each phase, medical writing supports the accurate reporting of adverse events, facilitates regulatory compliance, and contributes to ongoing drug safety evaluations, ultimately safeguarding public health and maintaining the integrity of the pharmaceutical industry.1
Pharmacovigilance medical writing has a significant impact on both the clinical development and post-marketing phases of drug development. It plays a vital role in documenting and analyzing safety data, helping to assess and manage risks throughout the drug's lifecycle. Additionally, it is crucial in preparing required submission documents, such as safety reports and risk management plans, which are necessary for regulatory authorities to evaluate the drug's safety profile before granting marketing authorization or approval.
The marketing authorization holder is responsible for continuously monitoring the safety of its medicinal products for human use, for informing the authorities of any changes that might have an impact on the marketing authorization, and for ensuring that the product information is kept up-to-date.2
Medical Writing in Pharmacovigilance 3
Medical writing involved in preparing various pharmacovigilance documents that needs to be submitted to regulatory authorities throughout the life cycle of any given medicinal product, starting with safety documentation required during clinical development, followed by safety documents required to support applications for marketing authorization, including RMPs, and finally those documents, such as the PSUR, that are required throughout the product’s post-marketing life. (ReferFigure 1).
Pharmacovigilance medical writing impacts on the clinical development and post-marketing phases, as well as making a significant contribution to the mandated submission documents required before the regulating authorities can grant marketing authorization/approval.
Medical writing plays a pivotal role in pharmacovigilance by crafting clear, precise, and regulatory-compliant documents that communicate safety information effectively.
Creation of Regulatory Documents: Medical writers are responsible for preparing a variety of regulatory documents required for the approval and ongoing assessment of pharmaceuticals.
These include:
Risk Management Plans (RMPs): These documents outline the identified and potential risks of a drug and describe measures to minimize these risks.
Periodic Safety Update Reports (PSURs): PSURs are critical for providing a comprehensive analysis of a drug's risk-benefit profile at regular intervals.
Development Safety Update Reports (DSURs): DSURs focus on the safety data collected during the clinical trial phase.
These documents must meet stringent regulatory requirements and present data in a clear and scientifically accurate manner.
Aggregate Reporting: Medical writers compile aggregate reports that integrate safety data from various sources over a specified period. These reports, such as PSURs and DSURs, are essential for ongoing risk assessment. They involve: 1. Data Analysis and Interpretation: Analyzing adverse event data to identify trends and new safety signals. 2.Literature Reviews: Reviewing published literature for new safety information related to the drug.3. Benefit-Risk Evaluation: Assessing the overall benefit-risk profile of the drug based on the accumulated safety data.
-
Individual Case Safety Reports (ICSRs): ICSRs document individual adverse events reported by healthcare professionals or patients. Medical writers play a role in
Signal Detection and Management: Medical writers support pharmacovigilance teams in signal detection and management by: 1. Documentation: Preparing documents that describe the detected signals, the methods used for detection, and the subsequent actions taken. Communication: Creating reports and summaries that communicate new safety signals to regulatory authorities and other stakeholders.
Standard Operating Procedures (SOPs): Medical writers contribute to the development and maintenance of SOPs that outline pharmacovigilance processes. These documents ensure consistency and compliance with regulatory requirements across pharmacovigilance activities.
-
Training Materials: To keep pharmacovigilance professionals informed about the latest guidelines and procedures, medical writers develop training materials, including:
Important Documents in Pharmacovigilance
Aggregate safety reports
Aggregate safety reports play a crucial role in assessing the safety of a medicinal product throughout its entire life cycle. While individual case safety reports offer insights into adverse events linked to a specific medication in a single patient, it is essential to analyze cumulative safety data collected globally. This broader analysis helps in understanding the overall safety profile and keeping track of the benefit-risk balance of the product.4
PBRER = periodic benefit-risk evaluation report
The goal of the Periodic Benefit-Risk Evaluation Report (PBRER) is to assess the balance between the benefits and risks of a medicinal product, considering new information in relation to cumulative data. It is submitted periodically by marketing authorization holders to regulatory authorities as a requirement during the post-authorization phase.5
Risk management plans (RMPs)
Risk Management Plans (RMPs) provide details on a medicine's safety profile, strategies for preventing or minimizing risks in patients, plans for studies and other activities to further understand the medicine's safety and efficacy, and methods for assessing the effectiveness of risk minimization measures.6
Development safety update report (DSUR)
The Development Safety Update Report (DSUR) provides safety information for drugs in clinical development. It serves to offer an annual, comprehensive review and evaluation of relevant safety data collected during the reporting period for an investigational drug, regardless of its market availability.
Periodic safety update reports (PSURs)
Periodic Safety Update Reports (PSURs) are pharmacovigilance documents designed to assess the risk-benefit profile of a medicinal product at specific intervals following its approval. The purpose of the PSUR is to offer a thorough and critical analysis of this risk-benefit balance, factoring in newly available safety data alongside existing information on the risks and benefits of the product.0007
Periodic adverse drug experience reports (PADERs)
Periodic Adverse Drug Experience Reports (PADERs) are cumulative safety reports required by the U.S. Food and Drug Administration (FDA) for products that have been approved for marketing in the United States. The submission of a PADER begins once a product has received marketing authorization. These reports are submitted on a quarterly and annual basis, with deadlines of 30 and 60 days after the data lock point, respectively. PADERs primarily present case reports involving serious, unlisted events (15-day alert reports), typically in narrative or tabular format. 4
Important documents for pharmacovigilance at different stages of drug developmentTable 1 8
Table 1
During Clinical development phase
Table 2
At the time marketing authorization applications
Table 3
After marketing authorization
Career as a Pharmacovigilance Writer9
Pharmacovigilance is an integral part of drug development & clinical research and is growing globally. Many pharmacovigilance centers are working for drug safety monitoring in this global boom, however, pharmacovigilance systems face major human resource challenges and there is a perennial need for skilled professionals. New drugs take a long time to market and there is a steep regulatory course in which safety forms a vital component for achieving the final goal of marketing authorization. Pharmacovigilance writers do not only work with pharmaceutical companies but can find employment with allied industry sectors like contract research organizations, BPO/KPOs, site management organizations, regulatory companies or consultants, government regulatory agencies, etc.
Many leading pharmaceutical companies today are looking for drug safety professionals to be a part of their industry and help in making a contribution with their efficient skills to this industry. The Professional Diploma in Pharmacovigilance and Pharmacoepidemiology is one of the courses that will provide the basis in pharmacovigilance principles and operations.
Conclusion
In summary, medical writing plays a crucial role in pharmacovigilance, acting as the foundation for clear and accurate communication of drug safety information. The accuracy and clarity of documents such as PSURs, PADERs, and RMPs are crucial for ensuring that regulatory authorities, healthcare professionals, and patients have access to up-to-date and reliable information about drug risks and benefits. Medical writers must navigate complex regulatory requirements and synthesize extensive clinical data to produce documents that uphold the highest standards of quality and compliance. As pharmacovigilance continues to evolve with advancements in drug development and regulatory expectations, the role of medical writing remains essential in safeguarding public health and maintaining the integrity of the pharmaceutical industry.